Inhibition of soluble epoxide hydrolase modulates inflammation and autophagy in obese adipose tissue and liver: Role for omega-3 epoxides

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 2, 2015, Pages 536-541

  López Vicario, Cristina ^a   Alcaraz Quiles, José ^a   García Alonso, Verónica ^a   Rius, Bibiana ^a   Hwang, Sung H ^b   Titos, Esther ^a,c   Lopategi, Aritz ^a   Hammock, Bruce D ^b   Arroyo, Vicente ^c,d   Clària, Joan ^a,c,e  

^a Department of Biochemistry and Molecular Genetics ^*  (Spain)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d UNIVERSITY OF BARCELONA   (Spain)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Autophagy; Inflammation; Obesity; Omega 3 derived epoxides; Soluble epoxide hydrolase

Indexed keywords

17,18 EPOXYEICOSATETRAENOIC ACID; 19,20 EPOXYDOCOSAPENTAENOIC; CYTOCHROME P450 1A1; CYTOCHROME P450 2E1; EPOXIDE; EPOXIDE HYDROLASE; HYDROLASE INHIBITOR; INITIATION FACTOR 2; INOSITOL REQUIRING ENZYME 1ALPHA; OMEGA 3 FATTY ACID; PALMITIC ACID; PROTEIN P62; SOLUBLE EPOXIDE HYDROLASE; SOLUBLE EPOXIDE HYDROLASE INHIBITOR; UNCLASSIFIED DRUG; 4-(4-(3-(4-TRIFLUOROMETHOXY-PHENYL)UREIDO)CYCLOHEXYLOXY)BENZOIC ACID; ACYL COENZYME A DESATURASE; BENZOIC ACID DERIVATIVE; CADHERIN; CARBANILAMIDE DERIVATIVE; CYTOCHROME P450; ENZYME INHIBITOR; FATH PROTEIN, MOUSE; OMEGA-3 FATTY ACID DESATURASE;

ADIPOCYTE; ADIPOSE TISSUE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; AUTOPHAGY; BROWN ADIPOSE TISSUE; CONJUGATE; CONTROLLED STUDY; ELECTROSPRAY MASS SPECTROMETRY; ENDOPLASMIC RETICULUM STRESS; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE EXPRESSION; IN VITRO STUDY; INCUBATION TIME; INFLAMMATION; INSULIN SENSITIVITY; LIPID PEROXIDATION; LIQUID CHROMATOGRAPHY; LIVER; LIVER CELL; MACROPHAGE; METABOLISM; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OBESITY; PHENOTYPE; POLARIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TANDEM MASS SPECTROMETRY; UPREGULATION; 3T3 CELL LINE; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; DRUG EFFECTS; FEMALE; GENETICS; MALE; MUTANT MOUSE STRAIN; PATHOLOGY; PHYSIOLOGY; TRANSGENIC MOUSE;

MUS;

3T3-L1 CELLS; ADIPOSE TISSUE; ANIMALS; AUTOPHAGY; BENZOATES; CADHERINS; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP2E1; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; EPOXIDE HYDROLASES; EPOXY COMPOUNDS; FATTY ACID DESATURASES; FATTY ACIDS, OMEGA-3; FEMALE; INFLAMMATION; LIVER; MALE; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; MICE, TRANSGENIC; OBESITY; PHENYLUREA COMPOUNDS;

EID: 84920897471     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1422590112     Document Type: Article

References (31)

1. Spector AA, Norris AW (2007) Action of epoxyeicosatrienoic acids on cellular function. Am J Physiol Cell Physiol 292(3):C996-C1012.
2. Zeldin DC (2001) Epoxygenase pathways of arachidonic acid metabolism. J Biol Chem 276(39):36059-36062.
3. Panigrahy D, et al. (2013) Epoxyeicosanoids promote organ and tissue regeneration. Proc Natl Acad Sci USA 110(33):13528-13533.
4. Arnold C, et al. (2010) Arachidonic acid-metabolizing cytochrome P450 enzymes are targets of ω-3 fatty acids. J Biol Chem 285(43):32720-32733.
5. Zhang G, et al. (2013) Epoxy metabolites of docosahexaenoic acid (DHA) inhibit angiogenesis, tumor growth, and metastasis. Proc Natl Acad Sci USA 110(16):6530-6535.
6. Ulu A, et al. (2014) An omega-3 epoxide of docosahexaenoic acid lowers blood pressure in angiotensin-II-dependent hypertension. J Cardiovasc Pharmacol 64(1): 87-99.
7. Morisseau C, et al. (2010) Naturally occurring monoepoxides of eicosapentaenoic acid and docosahexaenoic acid are bioactive antihyperalgesic lipids. J Lipid Res 51(12): 3481-3490.
8. Falck JR, et al. (2011) 17(R), 18(S)-epoxyeicosatetraenoic acid, a potent eicosapentaenoic acid (EPA) derived regulator of cardiomyocyte contraction: structure-activity relationships and stable analogues. J Med Chem 54(12):4109-4118.
9. Shen HC (2010) Soluble epoxide hydrolase inhibitors: A patent review. Expert Opin Ther Pat 20(7):941-956.
10. Morisseau C, Hammock BD (2013) Impact of soluble epoxide hydrolase and epoxyeicosanoids on human health. Annu Rev Pharmacol Toxicol 53:37-58.
11. Schmelzer KR, et al. (2005) Soluble epoxide hydrolase is a therapeutic target for acute inflammation. Proc Natl Acad Sci USA 102(28):9772-9777.
12. Shaik JS, et al. (2013) Soluble epoxide hydrolase inhibitor trans-4-[4-(3-adamantan- 1-yl-ureido)-cyclohexyloxy]-benzoic acid is neuroprotective in rat model of ischemic stroke. Am J Physiol Heart Circ Physiol 305(11):H1605-H1613.
13. López-Vicario C, et al. (2014) Molecular interplay between Δ5/Δ6 desaturases and long-chain fatty acids in the pathogenesis of non-alcoholic steatohepatitis. Gut 63(2): 344-355.
14. Kang JX, Wang J, Wu L, Kang ZB (2004) Transgenic mice: fat-1 mice convert n-6 to n-3 fatty acids. Nature 427(6974):504.
15. González-Périz A, et al. (2009) Obesity-induced insulin resistance and hepatic steatosis are alleviated by omega-3 fatty acids: A role for resolvins and protectins. FASEB J 23(6):1946-1957.
16. Serhan CN (2014) Pro-resolving lipid mediators are leads for resolution physiology. Nature 510(7503):92-101.
17. Rius B, et al. (2014) Resolvin D1 primes the resolution process initiated by calorie restriction in obesity-induced steatohepatitis. FASEB J 28(2):836-848.
18. DeTaeye BM, et al. (2010) Expression and regulation of soluble epoxide hydrolase in adipose tissue. Obesity (Silver Spring) 18(3):489-498.
19. Liu Y, et al. (2012) Inhibition of soluble epoxide hydrolase attenuates high-fat-diet- induced hepatic steatosis by reduced systemic inflammatory status in mice. PLoS ONE 7(6):e39165.
20. Yang L, Li P, Fu S, Calay ES, Hotamisligil GS (2010) Defective hepatic autophagy in obesity promotes ER stress and causes insulin resistance. Cell Metab 11(6):467-478.
21. Nuñez CE, et al. (2013) Defective regulation of adipose tissue autophagy in obesity. Int J Obes (Lond) 37(11):1473-1480.
22. Jansen HJ, et al. (2012) Autophagy activity is up-regulated in adipose tissue of obese individuals and modulates proinflammatory cytokine expression. Endocrinology 153(12):5866-5874.
23. Klionsky DJ, et al. (2012) Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 8(4):445-544.
24. Van Epps-Fung M, Williford J, Wells A, Hardy RW (1997) Fatty acid-induced insulin resistance in adipocytes. Endocrinology 138(10):4338-4345.
25. Buckley JD, Howe PRC (2009) Anti-obesity effects of long-chain omega-3 polyunsaturated fatty acids. Obes Rev 10(6):648-659.
26. Parker HM, et al. (2012) Omega-3 supplementation and non-alcoholic fatty liver disease: A systematic review and meta-analysis. J Hepatol 56(4):944-951.
27. Schneider JL, Cuervo AM (2014) Liver autophagy: Much more than just taking out the trash. Nat Rev Gastroenterol Hepatol 11(3):187-200.
28. Singh R, et al. (2009) Autophagy regulates adipose mass and differentiation in mice. J Clin Invest 119(11):3329-3339.
29. Bettaieb A, et al. (2013) Soluble epoxide hydrolase deficiency or inhibition attenuates diet-induced endoplasmic reticulum stress in liver and adipose tissue. J Biol Chem 288(20):14189-14199.
30. Oh DY, et al. (2010) GPR120 is an omega-3 fatty acid receptor mediating potent antiinflammatory and insulin-sensitizing effects. Cell 142(5):687-698.
31. Caviglia JM, et al. (2011) Different fatty acids inhibit apoB100 secretion by different pathways: unique roles for ER stress, ceramide, and autophagy. J Lipid Res 52(9): 1636-1651.